Phenmetrazines
What Are Phenmetrazines?
Phenmetrazines are phenmetrazine and closely related phenylmorpholine compounds. Phenmetrazine was investigated and used as an appetite-suppressing stimulant. More recent discussions often concern fluorinated relatives, especially 3-fluorophenmetrazine, abbreviated to 3-FPM.
The morpholine ring contains both nitrogen and oxygen within a six-membered ring. Phenmetrazine also carries phenyl and methyl substituents. This gives the family a different molecular framework from amphetamine, although selected members share its ability to promote monoamine release.
Phenmetrazine and Phendimetrazine
The similar names phenmetrazine and phendimetrazine refer to different compounds. Phendimetrazine has an additional methyl group on the nitrogen and can be metabolized to phenmetrazine. The activity of a metabolite is therefore relevant to interpreting the parent drug.
In experiments with rat brain preparations, phendimetrazine itself had no measurable effect on monoamine uptake or release under the conditions tested. Phenmetrazine, in contrast, released noradrenaline and dopamine. Its spatially different relative pseudophenmetrazine had a different profile. The researchers also measured changes in extracellular neurotransmitters in rats.
Placing phendimetrazine directly into a tissue preparation misses part of what happens after metabolism. An apparently inactive parent compound can still lead to an active exposure if the body converts it to another molecule.
What Fluorophenmetrazine Transporter Studies Show
The numbers in 2-FPM, 3-FPM and 4-FPM identify the position of fluorine on the aromatic ring. These are positional isomers: they share a molecular formula, but the atom is attached at a different location.
A comparison of the three fluorophenmetrazine isomers examined human monoamine transporters in cells and transmitter release from rat brain preparations. All three behaved as transporter substrates that could promote release. Their actions were more potent at dopamine and noradrenaline transporters than at the serotonin transporter.
The study provides a basis for expecting stimulant activity, but does not establish a complete human profile for any of the isomers. Serotonin activity was weaker in the assays, rather than proved absent at every possible exposure.
Analytical research on 3-FPM and its positional isomers also showed that the compounds could be distinguished using appropriate methods. A report that identifies only a fluorophenmetrazine without resolving the position leaves part of the chemical identity uncertain.
Early Human Pharmacokinetic Evidence
A 2019 analytical and pharmacokinetic investigation measured 3-FPM in samples collected during a controlled self-experiment. Much of the compound was excreted unchanged, while identified metabolic pathways included hydroxylation and oxidative opening of the morpholine ring.
This was a preliminary observation in one person, not a population pharmacokinetic study. Its estimates cannot describe the range of responses across people with different physiology or concurrent exposures. The work was also designed to identify and measure the compound, not to establish treatment benefit.
Pharmacokinetic evidence also answers a different question from a certificate of analysis. The latter documents the material submitted for testing; it does not establish how the human body distributes, transforms or eliminates that compound.
Hospital Cases Involve More Than One Substance
The Swedish STRIDA project reported 19 hospital cases with confirmed 3-FPM exposure. Clinical features included tachycardia, agitation, delirium, depressed consciousness and seizures. Six patients required intensive-care monitoring, five cases were graded as severe, and all patients survived.
Every patient also tested positive for other psychoactive substances. Benzodiazepines were the most common additional finding. This prevents the case series from defining a unique 3-FPM poisoning pattern or assigning all of the reduced consciousness and other symptoms to that compound.
The laboratory identified more 3-FPM exposures than had been recorded under that name during poison-centre consultations. What patients or clinicians initially call an exposure can therefore differ from what is detected. This uncertainty belongs in the interpretation of clinical safety reports, alongside the other substances present and the timing of symptoms.
Showing the single result

3-FPM
Price range: $410.00 through $8,715.00Select options This product has multiple variants. The options may be chosen on the product page